UCSF’s Renee Navarro and Amy Levine, both champions of diversity, played pivotal roles in the recent UC Diversity Pipeline Initiative, which encourages female students to pursue careers as faculty in the health sciences.
April 28, 2010
Leslie Benet, a professor in the schools of pharmacy and medicine, been honored with the premier prize from the American Society for Clinical Pharmacology and Therapeutics and his seventh honorary doctorate.
April 22, 2010
Insight into pneumonia deaths due to antibiotic-resistant Staphylococcus aureus infections emerges from UCSF study.
April 15, 2010
UCSF Chancellor Sue Desmond-Hellmann recently congratulated members of the UCSF community who have served at the University for a decade or longer.
March 19, 2010
The UCSF School of Pharmacy is charting new territory with an interdisciplinary education program for health care professionals on Medicare Part D.
March 18, 2010
Taking an innovative path toward personalized medicine, scientists for the first time will be able to eliminate – at an early point in a clinical trial — experimental drugs that show poor efficacy, dramatically shortening the time it takes to get the right medication to the right patient with breast cancer.
March 08, 2010
Dean Mary Anne Koda-Kimble, “a major force in shaping, advocating and expanding clinical pharmacy practice in the U.S. and around the world,” will receive the highest honor from the American Pharmacists Association.
March 03, 2010
New UCSF clinical trial tests intermittent high-dosage treatment for HER2-positive breast cancers.
March 01, 2010
A panel of experts appointed by Mayor Gavin Newsom recently presented an action plan as the approaching “age wave may bring a potential crisis in Alzheimer’s and dementia care” to San Francisco.
February 19, 2010
UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the American Journal of Transplantation that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.